GT McMahon, J Plutzky, E Daher, T Bhattacharyya, … - Diabetes care, 2005 - Am Diabetes Assoc RESULTS—After 3 months, HbA 1c levels dropped by 0.68% in the pioglitazone group and increased by
0.17% in the placebo group (P = 0.009 for difference between groups). Triglyceride (−93 vs. −39
mg/dl, P = 0.026) and HDL ... Cited by 15 - Related articles - All 5 versions
- ►adisonline.com [PDF] R Rajagopalan, A Perez, Z Ye, M Khan, FT … - Drugs &# 38; …, 2004 - ingentaconnect.com 1170-229X/04/0004-0259/$31.00/0 2004 Adis Data Information BV. All rights reserved. ... Rukmini
Rajagopalan, Alfonso Perez, Zhan Ye, Mehmood Khan and Frederick T. Murray ... Takeda
Pharmaceuticals North America Inc., ... Cited by 8 - Related articles - BL Direct - All 5 versions
R Jain, K Osei, S Kupfer, AT Perez, J Zhang - Pharmacotherapy, 2006 - PPI Rajeev Jain, MD, Kwame Osei, MD, Stuart Kupfer, MD, Alfonso T. Perez, MD, and Jeff Zhang, MS ...
Study Objective. To evaluate the long-term safety and efficacy of glyburide versus pioglitazone in
patients with a recent diagnosis of ... Cited by 10 - Related articles - BL Direct - All 9 versions
G Perriello, S Pampanelli, C Pietro, P … - Diabetic Medicine, 2006 - interscience.wiley.com Methods This was a double-blind, multicentre, comparative, parallel group trial in 283 patients with
Type 2 diabetes, who were randomized to receive 1-year treatment with pioglitazone 30–45 mg/day or
gliclazide 80–320 mg/day. Drug ... Cited by 10 - Related articles - BL Direct - All 4 versions
IB Frenchman - Current Therapeutic Research, 2003 - Elsevier Background: In the United States, type 2 diabetes mellitus (DM) is most prevalent among adults aged
>75 years. Judicious use of available therapies can improve plasma glucose concentration and reduce
the risk for complications in ... Cited by 2 - Related articles - All 4 versions
MK HELIÖVAARA, M Herz, AM TEPPO, E … - Journal of …, 2007 - cat.inist.fr Background: Type 2 diabetes is characterized by increased acute phase serum proteins. They are also
risk factors for cardiovascular disease. We wanted to study how improvement of glycemic control with
pioglitazone or glibenclamide ... Cited by 2 - Related articles - BL Direct
PK Sharma, A Bhansali, R Sialy, S Malhotra, P … - CLINICAL …, 2006 - medscape.com Adipose tissue is now recognized as an endocrine organ, which secretes several mediators with
diverse functions collectively known as adipocytokines. [1] One such adipocytokine, adiponectin has
been identified [2,3] and accounts ... Cited by 11 - Related articles - BL Direct - All 8 versions
CH Tseng, TS Huang - Diabetes research and clinical practice, 2005 - Elsevier Although the insulin-sensitizer pioglitazone is effective in improving glycemic control, decreasing
triglyceride (TG) and increasing high-density lipoprotein cholesterol (HDL-c), its effects on
low-density lipoprotein cholesterol ... Cited by 3 - Related articles - All 4 versions
[CITATION] Comparative clinical and budget evaluations of rosiglitazone and pioglitazone with …
M Boucher, L McAuley, A Brown, E Keely, B Skidmore - Ottawa: Canadian Coordinating …, 2003 Cited by 3 - Related articles
